With the failure of AbbVie’s emraclidine in two mid-stage trials, Bristol Myers Squibb’s Cobenfy is 'sole muscarinic winner.' ...

Dramatic study results point to the potential for a steroid-sparing option for patients with the underrecognized multiorgan ...

CHICAGO -- Researchers failed to prevent cognitive impairment in people with existing atrial fibrillation (Afib) by going the ...

AbbVie (ABBV) took a big hit after an adult schizophrenia drug missed its primary endpoint in mid-stage trials. Analysts are ...

Michigan’s pension bought Palantir, Intel, and CVS Health stock, while slashing an investment in Bristol Myers in the third ...

Fintel reports that on November 15, 2024, Wolfe Research initiated coverage of Bristol-Myers Squibb Company - Preferred ...

Fintel reports that on November 15, 2024, Wolfe Research initiated coverage of Bristol-Myers Squibb (NYSE:BMY) with a Peer ...

Bristol-Myers faces a renewed $6.7 billion lawsuit, alleging delayed approval for drugs like Breyanzi, affecting contingent ...

Why one trial participant's healthy birth after her CAR-T treatment for lupus is catching resesarchers' attention: ...

Bristol Myers Squibb (BMY) has received a recommendation for approval from an expert panel of the European Medicines Agency ...

Bristol Myers Squibb on Friday said the European Medicines Agency's Committee for Medicinal Products for Human Use recommended expanded approval of its Augtyro cancer drug in a pair of indications.

Wolfe Research analyst Alexandria Hammond initiated coverage of Bristol Myers (BMY) with a Peer Perform rating. Published first on TheFly ...